Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06506773 · ClinicalTrials.gov registry record
Natural History Study of Exocrine Pancreatic Function in Infants With Cystic Fibrosis (CF)
A clinical trial, sponsored by Vertex Pharmaceuticals Incorporated.
- Completed
- Registry status
- 79
- Enrollment target
NCT06506773 is a clinical trial that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 79 participants.
The verdict
NCT06506773 has completed, sponsored by Vertex Pharmaceuticals Incorporated.
- COMPLETED
- Registry status
- 79 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the natural history of exocrine pancreatic function by assessing Fecal elastase-1 (FE-1) in infants with CF during their first year of life.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2024-07-09 |
| Est. Completion | 2025-11-27 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06506773
The ClinicalTrials.gov registry entry for NCT06506773 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT06506773 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06506773 about?
NCT06506773 is a clinical study titled "Natural History Study of Exocrine Pancreatic Function in Infants With Cystic Fibrosis (CF)". The purpose of the study is to evaluate the natural history of exocrine pancreatic function by assessing Fecal elastase-1 (FE-1) in infants with CF during their first year of life.
What is the current status of trial NCT06506773?
This trial is currently completed. The enrollment target is 79 participants. The study started on 2024-07-09. Estimated completion is 2025-11-27.
Who is sponsoring clinical trial NCT06506773?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.